Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen de las Nieves (35)

2021

  1. MHC heterogeneity and response of metastases to immunotherapy

    Cancer and Metastasis Reviews, Vol. 40, Núm. 2, pp. 501-517

2020

  1. MHC class i molecules and cancer progression: Lessons learned from preclinical mouse models

    Cancer Immunology: A Translational Medicine Context, Second Edition (Springer International Publishing), pp. 189-204

  2. Restoration of mhc-i on tumor cells by fhit transfection promotes immune rejection and acts as an individualized immunotherapeutic vaccine

    Cancers, Vol. 12, Núm. 6, pp. 1-21

2018

  1. MHC intratumoral heterogeneity may predict cancer progression and response to immunotherapy

    Frontiers in Immunology, Vol. 9, Núm. JAN

2015

  1. Mhc class i molecules and cancer progression: Lessons learned from preclinical mouse models

    Cancer Immunology: A Translational Medicine Context (Springer Berlin Heidelberg), pp. 161-175

2014

  1. T lymphocytes restrain spontaneous metastases in permanent dormancy

    Cancer Research, Vol. 74, Núm. 7, pp. 1958-1968

2012

  1. MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells

    Carcinogenesis, Vol. 33, Núm. 3, pp. 687-693

  2. The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells

    Journal of Pathology, Vol. 227, Núm. 3, pp. 367-379

2011

  1. Immunotherapy eradicates metastases with reversible defects in MHC class i expression

    Cancer Immunology, Immunotherapy, Vol. 60, Núm. 9, pp. 1257-1268

2010

  1. Alterations of HLA class i expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 1, pp. 13-26

  2. The escape of cancer from T lymphocytes: Immunoselection of MHC class i loss variants harboring structural-irreversible "hard" lesions

    Cancer Immunology, Immunotherapy, Vol. 59, Núm. 10, pp. 1601-1606

2008

  1. The immunomodulator PSK induces in vitro cytotoxic activity in tumour cell lines via arrest of cell cycle and induction of apoptosis.

    BMC cancer, Vol. 8, pp. 78

2007

  1. Total loss of HLA class I expression on a melanoma cell line after growth in nude mice in absence of autologous antitumor immune response

    International Journal of Cancer, Vol. 121, Núm. 9, pp. 2023-2030

2006

  1. A new extract of the plant calendula officinalis produces a dual in vitro effect: Cytotoxic anti-tumor activity and lymphocyte activation

    BMC Cancer, Vol. 6

2004

  1. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: Implications for tumor immune escape

    Cancer Immunology, Immunotherapy

2003

  1. MHC class I antigens, immune surveillance, and tumor immune escape

    Journal of Cellular Physiology, Vol. 195, Núm. 3, pp. 346-355

  2. MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components

    International Journal of Cancer, Vol. 106, Núm. 4, pp. 521-527

  3. Tumour immunology, vaccination and escape strategies

    European Journal of Immunogenetics, Vol. 30, Núm. 3, pp. 177-183

2001

  1. Evidence of T cell immune selection in the generation of MHC class I-deficient metastatic tumor variants

    European Journal of Immunogenetics, Vol. 28, Núm. 2, pp. 324

  2. Generation of TAP-positive and TAP-negative metastases from a TAP-negative tumor clone

    European Journal of Immunogenetics, Vol. 28, Núm. 2, pp. 325